key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
Published 5 years ago • 97 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
2:03
long-term follow-up results from the zuma-1 trial in non-hodgkin lymphoma
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
1:41
zuma-1: 3-year follow-up on axi-cel in lbcl patients
-
3:32
zuma-1: updated data and future prospects
-
8:01
high-risk lymphoma: the zuma-1 and scholar-1 trials
-
1:15
primary overall survival analysis of the zuma-7 trial
-
0:43
safety findings for axi-cel in patients with dlbcl
-
1:09
dr. neelapu discusses efficacy of axi-cel in large b-cell lymphoma
-
3:58
zuma-1: a pivotal trial of car t-cells in nhl
-
2:00
zuma-1 trial: fda approval and follow-up of car t-cell product axicabtagene ciloleucel
-
3:55
zuma-12: axicabtagene ciloleucel for high-risk large b cell lymphoma
-
6:51
axicabtagene ciloleucel for patients with non-hodgkin lymphoma
-
2:40
zuma 2: how does prior btk inhibitor treatment affect the efficacy of kte-x19 in patients with mcl?
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
4:19
the pivotal zuma-1 trial for nhl
-
2:48
results from a subgroup analysis of zuma-3 and the efficacy of brexu-cel in r/r b-all
-
4:26
axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large b-cell lymphoma
-
6:03
2019 immuno-oncology policy summit key takeaways